Paper Details

  1. Home
  2. Paper Details

Meta-analysis of rivaroxaban and bleeding risk.

Author: EisenbergMark J, FilionKristian B, GrandiSonia M, WasserlaufGuila

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

This meta-analysis of five randomized controlled trials comparing rivaroxaban to vitamin K antagonists for stroke prevention, deep vein thrombosis, and pulmonary embolism found that rivaroxaban was not associated with an increased risk of bleeding overall. However, it was associated with a significant decrease in fatal bleeding.
Paper Details　
Original Abstract of the Article :
Rivaroxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unclear. Reported randomized controlled trials comparing the safety of rivaroxaban with that of vitamin K antagonists (warfarin, acenocoumar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.amjcard.2013.03.054

データ提供：米国国立医学図書館（NLM）

Rivaroxaban: A New Anticoagulant with a Favorable Safety Profile

The field of cardiovascular medicine is constantly evolving, seeking better ways to prevent blood clots and their devastating consequences. Rivaroxaban, a new oral anticoagulant, has emerged as a promising alternative to traditional vitamin K antagonists. But as with any new drug, concerns about its safety arise.

This meta-analysis, like a caravan traversing the vast desert, meticulously reviews data from five randomized controlled trials involving over 23,000 patients. The researchers carefully examined bleeding risks, including major and minor bleeding events, and mortality. They found that rivaroxaban was not associated with an increased risk of overall bleeding, but it was linked to a significant decrease in fatal bleeding.

The study also revealed a reduced risk of intracranial bleeding with rivaroxaban compared to vitamin K antagonists. However, the researchers found no significant difference in all-cause mortality.

Rivaroxaban: A Promising Alternative

The findings suggest that rivaroxaban may offer a favorable safety profile regarding bleeding risk, compared to traditional anticoagulants. The reduced risk of fatal bleeding is particularly encouraging, as it can significantly impact patient outcomes.

Dr. Camel's Conclusion

While more research is needed, this meta-analysis offers a glimmer of hope in the field of anticoagulation. Rivaroxaban holds promise as a safe and effective treatment option for preventing blood clots, potentially changing the landscape of cardiovascular care.

Date :
  1. Date Completed 2013-10-31
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

23642380

DOI: Digital Object Identifier

10.1016/j.amjcard.2013.03.054

Related Literature

Article Analysis
・Effects of rivaroxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.